|Videos|July 9, 2020

How California is Improving PrEP Access

A discussion around new data presented at AIDS 2020 which shows statewide strategies are breaking down barriers.

New findings assessing the value of the California Pre-exposure Prophylaxis (PrEP) Assistance Program since early 2018 shows the statewide program has benefitted particular populations of HIV-risk residents in the removal of financial and structural barriers to PrEP access.

The findings, presented at the International AIDS Society (IAS) AIDS 2020 Virtual Sessions this week, also showed that particular HIV-risk groups are still out of reach from proper PrEP protocol.

Namely, cisgender women, young adults, African Americans, and residents from the Central Valley are still under-enrolled in the California program.

How could this program—and clinical criticisms of it—serve to benefit other states and areas with heightened HIV cases?

In an interview with Contagion® as part of AIDS 2020 coverage, study author Philip J. Peters, MD, medical officer of the California Department of Public Health, discussed the study’s intent in bettering the state program, and what the program revealed about his state’s areas of need for bettered PrEP access.

“One is that there are number of out-of-pocket medical costs that can be a barrier to people accessing PrEP,” Peters said. “In particular, we’ve seen costs related to clinician visit expenses, costs related to medications beyond PrEP—and maybe most importantly are the laboratory costs.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.